A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea

Trial Profile

A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2018

At a glance

  • Drugs Surotomycin (Primary) ; Vancomycin
  • Indications Clostridium-difficile-infections; Diarrhoea; Intestinal infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms C-difficile
  • Sponsors Cubist Pharmaceuticals
  • Most Recent Events

    • 26 Feb 2018 A protocol has been amended with addition of primary safety endpoints and change in secondary endpoints.
    • 12 Apr 2016 Results assessing susceptibility and molecular epidemiology of Clostridium difficile presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
    • 12 Apr 2016 Primary endpoint of proportion of subjects with a clinical outcome of cure has not been met, according to results presented at the 26th European Congress of Clinical Microbiology and Infectious Disease.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top